<DOC>
	<DOCNO>NCT00269477</DOCNO>
	<brief_summary>The study design evaluate persistence bactericidal antibodies subject age 15 23 year ( yet 24 year ) vaccinate five year previously Study MTA02 participate Study MTA19 ( NCT 00777790 ) . In addition , kinetics antibody response evaluate subset participant receive booster dose Menactra® vaccine . This compare aged match control subject previously vaccinate meningococcal vaccine document meningitis disease also receive dose Menactra® vaccine .</brief_summary>
	<brief_title>Persistence Antibodies Adolescents Adults 15 23 Years Who Received One Dose Menactra® Menomune®</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subject healthy , determined medical history . Subject age 15 23 year ( yet 24 year ) . For subject participate Study MTA02 , subject previously receive one dose Menactra® vaccine Menomune®A/C/Y/W135 vaccine . Did participate Study MTA19 ( subset subject Study MTA02 recruit followup challenge study ) Subject parent/legal guardian sign Institutional Review Board ( IRB ) approve informed consent form subject sign IRBapproved assent form . Before recruitment second part study , subject thoroughly screen ensure able comply protocol specification A negative urine pregnancy test require menstruate female subject . History document invasive meningococcal disease . Received meningococcal vaccine Received vaccine ( desensitization therapy allergy ) 28day period prior enrollment Scheduled receive vaccination 28day period enrollment Received systemic antibiotic therapy within 72 hour prior collection blood sample Actively enrol schedule enrol another clinical study Serious chronic disease ( i.e. , cardiac , renal , neurologic , rheumatologic , metabolic , gastrointestinal , hematologic , psychiatric , organ system ) Known suspect impairment immunologic function Acute medical illness without fever within 72 hour oral temperature ≥ 100.4°F ( ≥ 38.0°C ) time inclusion Administration immune globulin , blood product , corticosteroid within 3 month study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Personal family history GuillainBarre Syndrome Suspected known hypersensitivity vaccine component Unavailable entire study period unable attend schedule visit comply study procedure Any condition , opinion investigator would pose health risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal infection</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
</DOC>